CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
TOP STORIES
In Depth: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
U.S. lawmakers’ push to scrutinize biotechnology ties with China is unsettling expectations for Chinese innovative-drug licensing and development deals overseas, threatening a fast-growing channel that has connected local drugmakers with global pharmaceutical companies.
Analysis: How Hong Kong’s New Tax Rules Will Transform Cross-Border Wealth Management
Register to read this article for free.
Register
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Save an extra $50. Introductory offer for new readers. Subscribe now.
Share this article
Open WeChat and scan the QR code
Sign in with Google
Sign in with Facebook
Sign in with 财新